Bayer says Xarelto and Eylea drugs near peak sales in 5-6 yrs
LEVERKUSEN, Germany (Reuters) - German drugmaker Bayer expects Xarelto and Eylea, among its most promising drugs, to be near their peak sales potential in about 5 to 6 years, Chief Executive Marijn Dekkers told a news conference on Friday.
He added that Bayer's Adempas and Xofigo drugs would likely reach peak sales somewhat later.
Earlier on Friday, Bayer lifted its estimate of the peak sales potential of its five most important drugs to at least 7.5 billion euros ($1.03 billion), up from more than 5.5 billion euros previously.
- U.S.-Israeli tensions rise as hostilities in Gaza subside |
- Family of five found shot dead in Maine home: police
- Pushing locals aside, Russians take top rebel posts in east Ukraine
- Sierra Leone Ebola patient, recovered from family, dies in ambulance
- Boko Haram kidnaps wife of Cameroon's vice PM, kills at least three
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video